Chawnshang Chang
Affiliations: | University of Rochester, Rochester, NY |
Area:
Neuroscience BiologyGoogle:
"Chawnshang Chang"Mean distance: 5624.53
Children
Sign in to add traineeHui-Kuan Lin | grad student | 2002 | Rochester |
Chih-Rong Shyr | grad student | 2002 | Rochester |
Huei-Ju Ting | grad student | 2002 | Rochester |
Yueh-Chiang Hu | grad student | 2003 | Rochester |
Wen-Jye Lin | grad student | 2003 | Rochester |
Mujib M. Rahman | grad student | 2003 | Rochester |
Saleh Altuwaijri | grad student | 2004 | Rochester |
Kuang-Hsiang Chuang | grad student | 2004 | Rochester |
Cheng-Lung Hsu | grad student | 2004 | Rochester |
Yei-Tsung Chen | grad student | 2006 | Rochester |
Shaozhen Xie | grad student | 2007 | Rochester |
Ning-Chun Liu | grad student | 2008 | Rochester |
Jiann-Jyh Lai | grad student | 2009 | Rochester |
Kuo-Pao Lai | grad student | 2010 | Rochester |
Wen-Lung Ma | grad student | 2010 | Rochester |
Chiung-Kuei Huang | grad student | 2011 | Rochester |
Shin-Jen Lin | grad student | 2013 | Rochester |
Tzu-Hua Lin | grad student | 2013 | Rochester |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Yang Y, Sheng J, Hu S, et al. (2022) Estrogen and G protein-coupled estrogen receptor accelerate the progression of benign prostatic hyperplasia by inducing prostatic fibrosis. Cell Death & Disease. 13: 533 |
Zhang M, Sun Y, Huang CP, et al. (2021) Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression. Cell Death & Disease. 12: 855 |
Deng G, Wang R, Sun Y, et al. (2021) Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals. Cell Death and Differentiation |
Lee SO, Ma Z, Yeh CR, et al. (2021) Corrigendum to: 'New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells'. Journal of Molecular Cell Biology |
You B, Sun Y, Luo J, et al. (2021) Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR. Oncogene |
Tian H, Chou FJ, Tian J, et al. (2021) ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling. Journal of Experimental & Clinical Cancer Research : Cr. 40: 3 |
Hu YC, Yeh S, Yeh SD, et al. (2020) Correction: Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. The Journal of Biological Chemistry. 295: 17382 |
Hu YC, Yeh S, Yeh SD, et al. (2020) Correction: Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. The Journal of Biological Chemistry. 295: 17382 |
Tian J, Ok Lee S, Liang L, et al. (2020) Correction: Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2'-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis. The Journal of Biological Chemistry. 295: 16469 |
Lin TH, Lee SO, Niu Y, et al. (2020) Correction: Differential androgen deprivation therapies with anti-androgens Casodex/bicalutamide or MDV3100/enzalutamide anti-androgen receptor ASC-J9 lead to promotion suppression of prostate cancer metastasis. The Journal of Biological Chemistry. 295: 15796 |